West Pharmaceutical Services, Inc.
WST
$230.11
$6.382.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.30% | -0.07% | -6.86% | -2.96% | 3.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.30% | -0.07% | -6.86% | -2.96% | 3.29% |
| Cost of Revenue | 4.69% | 5.03% | 2.30% | 4.47% | 1.63% |
| Gross Profit | -1.62% | -8.19% | -21.31% | -15.15% | 6.10% |
| SG&A Expenses | -8.16% | -7.98% | -6.11% | 0.81% | 154.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -100.00% | 250.00% | -- | -25.00% | 1,100.00% |
| Total Operating Expenses | 2.30% | 2.85% | 1.04% | 3.83% | 13.23% |
| Operating Income | 2.26% | -9.06% | -30.79% | -25.15% | -20.23% |
| Income Before Tax | -2.68% | -11.69% | -29.86% | -19.50% | 30.02% |
| Income Tax Expenses | 6.67% | 10.20% | -37.07% | -30.51% | 19.38% |
| Earnings from Continuing Operations | -5.04% | -15.69% | -28.24% | -17.64% | 33.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.04% | -15.69% | -28.24% | -17.64% | 33.01% |
| EBIT | 2.26% | -9.06% | -30.79% | -25.15% | -20.23% |
| EBITDA | 4.22% | -5.53% | -23.87% | -19.16% | -15.64% |
| EPS Basic | -3.21% | -13.95% | -26.96% | -16.52% | 33.55% |
| Normalized Basic EPS | 4.40% | -9.37% | -29.51% | -22.88% | -19.02% |
| EPS Diluted | -2.10% | -13.55% | -26.70% | -16.22% | 33.40% |
| Normalized Diluted EPS | 4.80% | -8.90% | -29.14% | -22.48% | -18.70% |
| Average Basic Shares Outstanding | -1.89% | -2.02% | -1.75% | -1.34% | -0.40% |
| Average Diluted Shares Outstanding | -2.27% | -2.52% | -2.25% | -1.85% | -0.79% |
| Dividend Per Share | 5.00% | 5.26% | 5.26% | 5.26% | 5.26% |
| Payout Ratio | 0.09% | 0.23% | 0.44% | 0.27% | -0.21% |
